Treatment of cancer with dual targeting of CD47 and EGFR
Provided is a method for targeting cells, including not limited to cancer cells, to achieve depletion in a regimen comprising contacting the targeted cells with an agent comprising (i) an agent that blocks CD47 activity; and (ii) an antibody that specifically binds to EGFR. In some embodiments, the cancer cells have a mutant form of one or more of KRAS, NRAS, or BRAF. The level of depletion of the targeted cells is enhanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 06. Jan. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
WEISSMAN IRVING L [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-01-06, Last update posted on www.tib.eu: 2023-07-31, Last updated: 2023-08-04 |
|---|
| Patentnummer: |
CN115569192 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA016619706 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA016619706 | ||
| 003 | DE-627 | ||
| 005 | 20230804092032.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230607s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA016619706 | ||
| 035 | |a (EPA)CN115569192 | ||
| 035 | |a (EPA)59013321 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a WEISSMAN IRVING L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment of cancer with dual targeting of CD47 and EGFR |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-01-06, Last update posted on www.tib.eu: 2023-07-31, Last updated: 2023-08-04 | ||
| 520 | |a Provided is a method for targeting cells, including not limited to cancer cells, to achieve depletion in a regimen comprising contacting the targeted cells with an agent comprising (i) an agent that blocks CD47 activity; and (ii) an antibody that specifically binds to EGFR. In some embodiments, the cancer cells have a mutant form of one or more of KRAS, NRAS, or BRAF. The level of depletion of the targeted cells is enhanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a MCKENNA KELLY MARIE |4 aut | |
| 700 | 0 | |a WILLINGHAM STEPHEN |4 aut | |
| 700 | 0 | |a HO DORIS PO YI |4 aut | |
| 700 | 0 | |a DALERBA PIERO D |4 aut | |
| 700 | 0 | |a VOLKMER JENS-PETER |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 06. Jan. |
| 773 | 1 | 8 | |g year:2023 |g day:06 |g month:01 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/59013321/publication/CN115569192A1?q=CN115569192 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 06 |c 01 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 06 |c 01 | ||